Financial Analysis: Affymax (OTCMKTS:AFFY) versus Arvinas (NASDAQ:ARVN)

Affymax (OTCMKTS:AFFY) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Insider & Institutional Ownership

95.2% of Arvinas shares are owned by institutional investors. 1.6% of Affymax shares are owned by company insiders. Comparatively, 4.7% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Affymax and Arvinas, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Affymax	0	0	0	0	0.00
Arvinas	2	7	10	0	2.42

Arvinas has a consensus price target of $13.88, suggesting a potential upside of 33.23%. Given Arvinas’ stronger consensus rating and higher possible upside, analysts clearly believe Arvinas is more favorable than Affymax.

Profitability

This table compares Affymax and Arvinas’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Affymax	N/A	N/A	N/A
Arvinas	-30.77%	-14.25%	-9.31%

Valuation and Earnings

This table compares Affymax and Arvinas”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Affymax	N/A	N/A	N/A	N/A	N/A
Arvinas	$262.60 million	2.54	-$80.80 million	($1.28)	-8.14

Affymax has higher earnings, but lower revenue than Arvinas.

Volatility & Risk

Affymax has a beta of 8.09, suggesting that its share price is 709% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500.

Summary

Arvinas beats Affymax on 6 of the 10 factors compared between the two stocks.

About Affymax

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

About Arvinas

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.